Free Trial

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Position Raised by Barclays PLC

Dianthus Therapeutics logo with Medical background

Barclays PLC lifted its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 390.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,684 shares of the company's stock after buying an additional 33,185 shares during the period. Barclays PLC owned approximately 0.14% of Dianthus Therapeutics worth $1,141,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Quest Partners LLC raised its position in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after acquiring an additional 1,124 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Dianthus Therapeutics by 104.0% in the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company's stock worth $242,000 after purchasing an additional 4,506 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $236,000. Fred Alger Management LLC lifted its stake in Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company's stock valued at $264,000 after purchasing an additional 3,316 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new stake in Dianthus Therapeutics during the second quarter worth approximately $265,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock traded down $1.24 during mid-day trading on Monday, hitting $21.50. The company's stock had a trading volume of 125,604 shares, compared to its average volume of 205,671. Dianthus Therapeutics, Inc. has a 52-week low of $10.22 and a 52-week high of $33.77. The firm's 50 day moving average is $25.23 and its 200 day moving average is $26.69. The company has a market cap of $636.34 million, a PE ratio of -8.60 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $2.17 million during the quarter, compared to analysts' expectations of $1.07 million. As a group, analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Analyst Upgrades and Downgrades

DNTH has been the topic of several research reports. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. TD Cowen assumed coverage on Dianthus Therapeutics in a report on Friday, December 20th. They issued a "buy" rating on the stock. Oppenheimer upped their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a report on Monday, November 11th. Finally, Raymond James raised Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $46.43.

View Our Latest Stock Analysis on Dianthus Therapeutics

Dianthus Therapeutics Company Profile

(Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Further Reading

Institutional Ownership by Quarter for Dianthus Therapeutics (NASDAQ:DNTH)

Should You Invest $1,000 in Dianthus Therapeutics Right Now?

Before you consider Dianthus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.

While Dianthus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines